JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Listă Acțiuni・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Închisă

SectorSănătate

301.71 1.32

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

294.94

Maxim

302.34

Indicatori cheie
By Trading Economics
Venit	-65M 186M
Vânzări	-152M 1.1B
P/E Medie Sector	131.842 67.147
EPS	1.25
Marjă de profit	16.993
Angajați	2,500
EBITDA	-152M 145M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+50.75% upside

Dividende
By Dow Jones
Următoarele câștiguri	30 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.1B 41B
Deschiderea anterioară	300.39
Închiderea anterioară	301.71

Sentimentul știrilor

By Acuity

16%

84%

29 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

256.565 / 269.81 Suport & Rezistență

Alnylam Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mai 2026, 22:17 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mai 2026, 23:47 UTC

Câștiguri

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mai 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Shareholders to Own About 51% of Combined Company

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Board Unanimously Endorsed, Supported Deal

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Deal Unanimously Recommended by Vault Board

4 mai 2026, 22:39 UTC

Achiziții, Fuziuni, Preluări

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources to Acquire All Ordinary Shares in Vault

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mai 2026, 22:37 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mai 2026, 22:26 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mai 2026, 22:02 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mai 2026, 21:52 UTC

Câștiguri

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mai 2026, 21:49 UTC

Câștiguri

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mai 2026, 21:43 UTC

Câștiguri

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mai 2026, 21:41 UTC

Câștiguri

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mai 2026, 21:40 UTC

Câștiguri

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparație

Modificare preț

Alnylam Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

50.75% sus

Prognoză pe 12 luni

Medie 449.12 USD 50.75%

Maxim 550 USD

Minim 330 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAlnylam Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor Alnylam Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

256.565 / 269.81Suport & Rezistență

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

29 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.